DE3120460C2 - - Google Patents
Info
- Publication number
- DE3120460C2 DE3120460C2 DE3120460A DE3120460A DE3120460C2 DE 3120460 C2 DE3120460 C2 DE 3120460C2 DE 3120460 A DE3120460 A DE 3120460A DE 3120460 A DE3120460 A DE 3120460A DE 3120460 C2 DE3120460 C2 DE 3120460C2
- Authority
- DE
- Germany
- Prior art keywords
- rifamycin
- imidazolo
- strong
- deoxy
- weak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims description 47
- 229940109171 rifamycin sv Drugs 0.000 claims description 32
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 claims description 20
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 claims description 11
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- 238000002211 ultraviolet spectrum Methods 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229930189077 Rifamycin Natural products 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 229930193140 Neomycin Natural products 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 150000003927 aminopyridines Chemical class 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 150000002537 isoquinolines Chemical class 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 229960003292 rifamycin Drugs 0.000 description 5
- 229960003040 rifaximin Drugs 0.000 description 5
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- -1 hydroxyl rifamycin derivatives Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 229940081192 rifamycins Drugs 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- CMBSSVKZOPZBKW-UHFFFAOYSA-N 5-methylpyridin-2-amine Chemical compound CC1=CC=C(N)N=C1 CMBSSVKZOPZBKW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 239000004425 Makrolon Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- XTPGUQSTSWYULT-ZDHWWVNNSA-N Rifamycin P Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)c5scnc5c4c3C2=O XTPGUQSTSWYULT-ZDHWWVNNSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229950011175 aminopicoline Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- OSILBMSORKFRTB-UHFFFAOYSA-N isoquinolin-1-amine Chemical compound C1=CC=C2C(N)=NC=CC2=C1 OSILBMSORKFRTB-UHFFFAOYSA-N 0.000 description 1
- JEHCHYAKAXDFKV-UHFFFAOYSA-J lead tetraacetate Chemical compound CC(=O)O[Pb](OC(C)=O)(OC(C)=O)OC(C)=O JEHCHYAKAXDFKV-UHFFFAOYSA-J 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 229950003104 rifamide Drugs 0.000 description 1
- VFYNXKZVOUXHDX-VDPUEHCXSA-N rifamycin b diethylamide Chemical compound CC1=C(O)C(C=2O)=C3C(OCC(=O)N(CC)CC)=CC=2NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]2(C)OC1=C3C2=O VFYNXKZVOUXHDX-VDPUEHCXSA-N 0.000 description 1
- XTPGUQSTSWYULT-TXXBDZDDSA-N rifamycin p Chemical compound OC1=C(C(O)=C2C)C3=C4N=CSC4=C1NC(=O)\C(C)=C\C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O XTPGUQSTSWYULT-TXXBDZDDSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT03429/80A IT1154655B (it) | 1980-05-22 | 1980-05-22 | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3120460A1 DE3120460A1 (de) | 1982-03-11 |
| DE3120460C2 true DE3120460C2 (OSRAM) | 1990-12-13 |
Family
ID=11107198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19813120460 Granted DE3120460A1 (de) | 1980-05-22 | 1981-05-22 | Pyridoimidazolorifamycinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4341785A (OSRAM) |
| JP (1) | JPS5711987A (OSRAM) |
| AR (1) | AR226212A1 (OSRAM) |
| AT (1) | AT373599B (OSRAM) |
| AU (1) | AU537093B2 (OSRAM) |
| BE (1) | BE888895A (OSRAM) |
| CA (1) | CA1142518A (OSRAM) |
| CH (1) | CH648037A5 (OSRAM) |
| DE (1) | DE3120460A1 (OSRAM) |
| DK (1) | DK157876C (OSRAM) |
| EG (1) | EG14891A (OSRAM) |
| ES (1) | ES8203388A1 (OSRAM) |
| FI (1) | FI69467C (OSRAM) |
| FR (1) | FR2482967A1 (OSRAM) |
| GB (1) | GB2079270B (OSRAM) |
| GR (1) | GR75640B (OSRAM) |
| IE (1) | IE51204B1 (OSRAM) |
| IT (1) | IT1154655B (OSRAM) |
| LU (1) | LU83376A1 (OSRAM) |
| NL (1) | NL187022C (OSRAM) |
| NO (1) | NO155622C (OSRAM) |
| PH (2) | PH17207A (OSRAM) |
| PT (1) | PT73064B (OSRAM) |
| SE (1) | SE453089B (OSRAM) |
| ZA (1) | ZA813430B (OSRAM) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
| IT1264494B1 (it) * | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US5981522A (en) * | 1995-09-01 | 1999-11-09 | Kaneka Corporation | Treatment of disease caused by infection of Helicobacter |
| ES2237809T3 (es) * | 1997-02-28 | 2005-08-01 | Kaneka Corporation | Medicina curativa para la enfermedad causada por infeccion de helicobacter. |
| EP1453837A4 (en) * | 2001-11-21 | 2007-11-07 | Activbiotics Inc | TARGETED THERAPEUTIC AGENTS AND USES THEREOF |
| AU2002364162A1 (en) * | 2001-12-13 | 2003-06-30 | Activbiotics, Inc. | Sulfhydryl rifamycins and uses thereof |
| EP1560566B1 (en) * | 2002-11-05 | 2012-04-11 | Fadim S.r.l. | Controlled and continued delivery of rifaximin |
| US7820652B2 (en) * | 2003-09-24 | 2010-10-26 | Activbiotics Pharma, Llc | Regimen for the administration of rifamycin-class antibiotics |
| ITMI20032144A1 (it) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| US7906542B2 (en) * | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
| US7902206B2 (en) * | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
| US20080262024A1 (en) * | 2003-11-07 | 2008-10-23 | Giuseppe Claudio Viscomi | Rifaximin compositions and method of use |
| US7923553B2 (en) * | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
| US7256187B2 (en) * | 2004-03-10 | 2007-08-14 | Cumbre Pharmaceuticals Inc. | Rifamycin C-11 oxime derivatives effective against drug-resistant microbes |
| US7265107B2 (en) * | 2004-03-10 | 2007-09-04 | Cumbre Pharmaceuticals Inc. | Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes |
| US7202246B2 (en) * | 2004-06-09 | 2007-04-10 | Cumbre Pharmaceuticals Inc. | Spiro-rifamycin derivatives targeting RNA polymerase |
| US20060210483A1 (en) * | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections |
| US20060210492A1 (en) * | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Use of rifaximin for treatment and prevention of periodontal conditions |
| US8003118B2 (en) * | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
| DK1698630T3 (da) | 2005-03-03 | 2014-12-08 | Alfa Wassermann Spa | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| BRPI0614758A2 (pt) | 2005-08-11 | 2011-04-12 | Targanta Therapeutics Inc | rifamicinas fosfonadas e usos destas para a prevenção e tratamento de infecções na articulação e osso |
| US8987292B2 (en) | 2006-03-09 | 2015-03-24 | Salix Pharmaceuticals, Ltd. | Rifaximin anti-rectal dysfunction preparation |
| PT2054066E (pt) | 2006-08-02 | 2015-07-16 | Salix Pharmaceuticals Inc | Métodos para tratamento de enterite por radiação |
| ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
| US8633234B2 (en) * | 2006-09-22 | 2014-01-21 | Cipla Limited | Rifaximin |
| US20080159987A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Restless Legs Syndrome |
| US20080161337A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Chronic Prostatitis |
| ITMI20071241A1 (it) * | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
| ES2389358T5 (es) | 2007-07-06 | 2016-01-19 | Lupin Ltd. | Composiciones farmacéuticas de rifaximina |
| US8383151B2 (en) | 2007-07-06 | 2013-02-26 | Lupin Limited | Pharmaceutical compositions of rifaximin |
| US7709634B2 (en) * | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
| SG10201607926VA (en) | 2008-02-25 | 2016-11-29 | Salix Pharmaceuticals Ltd | Forms of rifaximin and uses thereof |
| US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| KR20100122937A (ko) | 2008-02-26 | 2010-11-23 | 샐릭스 파마슈티컬스 리미티드 | 장 질환의 치료 방법 |
| US11779571B2 (en) | 2008-02-26 | 2023-10-10 | Salix Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome (IBS) |
| AU2009244190B2 (en) | 2008-05-07 | 2016-02-25 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel disease by administering a bowel cleanser and an antibiotic |
| EP2324041A4 (en) | 2008-08-13 | 2012-06-13 | Targanta Therapeutics Corp | PHOSPHONIZED RIFAMYCINS AND ITS APPLICATION FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS |
| AU2009297562B2 (en) | 2008-09-26 | 2015-04-23 | Alfasigma S.P.A. | Agent for preventing and/or treating functional gastrointestinal disorder |
| ES2770308T3 (es) | 2008-10-02 | 2020-07-01 | Salix Pharmaceuticals Ltd | Procedimientos de tratamiento de encefalopatía hepática |
| US12285414B2 (en) | 2008-10-02 | 2025-04-29 | Salix Pharmaceuticals, Inc. | Methods of treating hepatic encephalopathy |
| KR20110107806A (ko) | 2008-12-10 | 2011-10-04 | 시플라 리미티드 | 리팍시민 복합체 |
| IT1397617B1 (it) * | 2009-04-20 | 2013-01-18 | Alfa Wassermann Spa | Nuovi derivati della rifamicina |
| BRPI1010028A2 (pt) | 2009-06-02 | 2019-02-12 | Salix Pharmaceuticals, Ltd. | métodos de tratamento de encefalopatia hepática |
| EP2475392A4 (en) | 2009-09-13 | 2013-01-09 | Salix Pharmaceuticals Ltd | METHOD FOR TREATING IRRITATION SYNDROME |
| KR20190000931A (ko) | 2009-10-27 | 2019-01-03 | 루핀 리미티드 | 리팍시민의 고형 분산물 |
| KR20120117788A (ko) | 2009-11-23 | 2012-10-24 | 시플라 리미티드 | 국소용 폼 조성물 |
| US8952159B2 (en) | 2009-12-28 | 2015-02-10 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
| EP3650022A1 (en) | 2010-02-18 | 2020-05-13 | Salix Pharmaceuticals, Ltd. | Methods for treating rifampin resistant clostridium difficilis infections |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| EP2544660B1 (en) | 2010-03-10 | 2018-06-13 | Lupin Limited | Rifaximin ready-to-use suspension |
| EP3750526A1 (en) | 2010-07-12 | 2020-12-16 | Salix Pharmaceuticals, Inc. | Formulations of rifaximin and uses thereof |
| US8759513B2 (en) | 2010-09-13 | 2014-06-24 | Sequent Scientific Limited | Polymorphic form of rifaximin and process for its preparation |
| MX350448B (es) | 2011-02-11 | 2017-09-07 | Salix Pharmaceuticals Ltd | Formas de rifaximina y usos de las mismas. |
| AU2012251385A1 (en) | 2011-05-02 | 2013-11-21 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
| ITMI20110890A1 (it) | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| RU2496475C2 (ru) | 2011-10-26 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция и набор для лечения бактериальных инфекций |
| PL2773205T3 (pl) | 2011-11-02 | 2024-09-02 | Salix Pharmaceuticals, Inc. | Ryfaksymina w leczeniu ustępującej biegunki z przewagą zespołu jelita drażliwego |
| JP2015509105A (ja) | 2012-01-25 | 2015-03-26 | サリックス ファーマスーティカルズ，リミテッド | リファキシミン誘導体及びその使用 |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| US9849090B2 (en) | 2012-12-12 | 2017-12-26 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of rifaximin |
| EP2971062A2 (en) | 2013-03-15 | 2016-01-20 | ALFA WASSERMANN S.p.A. | Method for diagnosing vaginal infections |
| WO2014140988A1 (en) | 2013-03-15 | 2014-09-18 | Alfa Wassermann S.P.A. | Rifaximin for use in the treating of vaginal infections. |
| ES2829285T3 (es) | 2013-04-12 | 2021-05-31 | Alfasigma Spa | Administración de AINE y composiciones, métodos y sistemas relacionados |
| US9018225B1 (en) | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
| EP2927235B1 (en) | 2014-03-31 | 2017-02-08 | Euticals S.P.A. | Polymorphic mixture of rifaximin and its use for the preparation of solid formulations |
| EP3134415A4 (en) * | 2014-04-19 | 2017-10-25 | Granules India Limited | An improved process for the preparation of rifamycin derivatives |
| WO2015171493A1 (en) | 2014-05-04 | 2015-11-12 | Salix Pharmaceuticals, Inc. | Ibs microbiota and uses thereof |
| PL3143027T3 (pl) | 2014-05-12 | 2019-11-29 | Alfasigma Spa | Nowe solwatowane krystaliczne postaci rifaksyminy, ich wytwarzanie, kompozycje i zastosowania |
| EP2982764A1 (en) | 2014-08-05 | 2016-02-10 | ALFA WASSERMANN S.p.A. | Identification of vaginal bacteria |
| US9988398B2 (en) | 2016-06-07 | 2018-06-05 | Cadila Healthcare Limited | Crystalline form of rifaximin and process for its preparation |
| EP4137132A1 (en) | 2016-09-30 | 2023-02-22 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
| IT201700091912A1 (it) * | 2017-08-08 | 2019-02-08 | Biofer Spa | Nuove pirido-imidazo rifamicine |
| RU2020102511A (ru) | 2017-06-26 | 2021-07-27 | Биофер С.П.А. | Соединения пиридо-имидазо рифамицина в качестве антибактериального средства |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE273377C (OSRAM) * | ||||
| AT273377B (de) * | 1967-03-01 | 1969-08-11 | Lepetit Spa | Verfahren zur Herstellung von neuen Rifamycinen |
| AT344898B (de) * | 1975-06-13 | 1978-08-10 | Archifar Ind Chim Trentino | Verfahren zur herstellung neuer rifamycin-verbindungen |
| DK345977A (da) * | 1976-09-30 | 1978-03-31 | Archifar Ind Chim Trentino | G rifamycinforbindelser og fremgangsmaade til deres fremstillin |
| CH629212A5 (it) * | 1976-10-18 | 1982-04-15 | Erba Farmitalia | Procedimento per la preparazione di composti di rifamicina. |
| CH633014A5 (en) * | 1978-06-09 | 1982-11-15 | Erba Farmitalia | Rifamycin compounds |
-
1980
- 1980-05-22 IT IT03429/80A patent/IT1154655B/it active Protection Beyond IP Right Term
-
1981
- 1981-05-11 NL NLAANVRAGE8102290,A patent/NL187022C/xx not_active IP Right Cessation
- 1981-05-11 US US06/262,123 patent/US4341785A/en not_active Expired - Lifetime
- 1981-05-18 AU AU70655/81A patent/AU537093B2/en not_active Expired
- 1981-05-19 AT AT0222781A patent/AT373599B/de not_active IP Right Cessation
- 1981-05-20 PH PH25656A patent/PH17207A/en unknown
- 1981-05-20 FR FR8110058A patent/FR2482967A1/fr active Granted
- 1981-05-20 GR GR65010A patent/GR75640B/el unknown
- 1981-05-20 PT PT73064A patent/PT73064B/pt unknown
- 1981-05-20 LU LU83376A patent/LU83376A1/fr unknown
- 1981-05-20 EG EG280/81A patent/EG14891A/xx active
- 1981-05-21 ES ES502906A patent/ES8203388A1/es not_active Expired
- 1981-05-21 FI FI811565A patent/FI69467C/fi not_active IP Right Cessation
- 1981-05-21 BE BE2/59169A patent/BE888895A/fr not_active IP Right Cessation
- 1981-05-21 IE IE1139/81A patent/IE51204B1/en not_active IP Right Cessation
- 1981-05-21 ZA ZA00813430A patent/ZA813430B/xx unknown
- 1981-05-21 DK DK224781A patent/DK157876C/da active
- 1981-05-21 CA CA000378015A patent/CA1142518A/en not_active Expired
- 1981-05-21 SE SE8103216A patent/SE453089B/sv not_active IP Right Cessation
- 1981-05-21 NO NO811731A patent/NO155622C/no unknown
- 1981-05-22 DE DE19813120460 patent/DE3120460A1/de active Granted
- 1981-05-22 GB GB8115790A patent/GB2079270B/en not_active Expired
- 1981-05-22 JP JP7787781A patent/JPS5711987A/ja active Granted
- 1981-05-22 AR AR285424A patent/AR226212A1/es active
- 1981-05-22 CH CH3381/81A patent/CH648037A5/de not_active IP Right Cessation
-
1982
- 1982-02-09 PH PH26842A patent/PH18704A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3120460C2 (OSRAM) | ||
| DE3005164C2 (de) | 1,1-Dioxopenicillanoyloxymethyl-6-(D-α-amino-α-phenylacetamido)-penicillanat, Verfahren zu seiner Herstellung und es enthaltendes Arzneimittel | |
| DE3611194A1 (de) | Cancerostatisches mittel | |
| DE2102172A1 (de) | Neue Mitel zur Behandlung und Pflege der Haut | |
| DE3149359A1 (de) | Pharmazeutische zubereitung zur behandlung und verhinderung von entzuendlichen darmkrankheiten, neue salze der 5,5'-azobissalicylsaeure und verfahren zur herstellung dieser salze | |
| DE2143369A1 (de) | Neue Pyridopyrimidincarbonsäurederivate und Verfahren zu deren Herstellung | |
| DE2462691C2 (OSRAM) | ||
| DE3714937C2 (de) | Neue Retinsäureester von Antibiotika, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische und kosmetische Zusammensetzungen | |
| DE2504045C3 (de) | 16,17 Dihydro-apovincaminsäure-2hydroxypropylester, deren Salze, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE2140719A1 (de) | Arzneimittel auf der Grundlage eines Pyrazolons | |
| DE2641388C3 (de) | 3',4'-Didesoxykanamycin B-N-methansulfonsäuren und deren Alkalimetallsalze sowie diese Verbindungen enthaltende pharmazeutische Präparate | |
| DE2149750A1 (de) | Erythromycin-Derivate | |
| DE1943781A1 (de) | Erythromycylamin und Verfahren zu seiner Herstellung | |
| DE69309461T2 (de) | Zusammensetzung zur Beschleunigung der Wundheilung | |
| DE3204630C2 (OSRAM) | ||
| DE1931466C3 (de) | Kupfer (Il)-komplexe von 6-Niederalkoxy-1-phenazinol- 5,10 - dioxiden | |
| DE2917890C2 (OSRAM) | ||
| DE2244265A1 (de) | Neue imidazolderivate, ihre herstellung und die medizinischen zusammensetzungen, die sie enthalten | |
| DE3236191C2 (de) | Chlorhexidin-Dinaproxenat, Verfahren zu dessen Herstellung, sowie dieses enthaltende anti-entzündliche, desinfizierende und anti-bakterielle Zusammensetzung | |
| DE2835987A1 (de) | 3-amino-17a-aza-d-homo-5 alpha -androstanderivate und quaternaere salze davon sowie verfahren zu ihrer herstellung | |
| DE1915829C3 (de) | Niedere Acyljosamycine, Verfahren zu ihrer Herstellung und Arzneimittel mit einem Gehalt an diesen Verbindungen | |
| DE1932704C (de) | 2 Hydroxy und 2 Alkoxy 5 nitro benzyl hexamethylen tetrammonium salze | |
| DE2549863C3 (de) | Pyridoxyliden-p-amino-benzoesäurederivate, deren Herstellung und Verwendung | |
| DE2307795C3 (de) | 11 beta 17alpha, 21 Trihydroxy-6 | |
| AT267512B (de) | Verfahren zur Herstellung von reinem Methdilazinsulfoxyd und seinen Salzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |